Belinda Bailey and David Eedes of Icon were invited to present the ICON Chemotherapy Administration Standards & Guidelines to delegates on the recent SASCRO/SASMO 2017 Conference. They would like to share the slide set and abstract from the prestigious national event with you on the Icon website.Read more ICON Chemotherapy Administration Standards & Guidelines published
The literature and evidence for the use of erythropoietin in treating cancer patients with anaemia has recently been the subject of a review in UpToDate®.Read more Literature Review on the Use of Erythropoiesis-stimulating Agents ESAs in Anaemia in Cancer Patients
Results from a large clinical trial show that patients with bone metastases from certain cancers can receive less frequent zoledronic acid without sacrificing efficacy.Read more Longer dosing interval for zoledronic acid for bone metastases is no less effective than standard-dosing interval
David Eedes shares his thoughts on two recent articles in the January JAMA debating the use of chemotherapy in the treatment of non-metastatic prostate cancer.Read more Chemotherapy in Non-metastatic Prostate Cancer – Can we justify it?
In prostate cancer awareness month, men – especially if they are over 50 – are encouraged to get themselves tested for this disease. But, says a leading oncologist, more needs to be done to counsel patients upfront about the pros and cons of prostate cancer screening and risks of over-diagnosis.Read more Prostate cancer: ‘Over diagnosis’ can cause more harm than good